Studies on Growth Characteristics and Cross-Neutralization of Wild-Type and Delta SARS-CoV-2 From Hisar (India)

Nitin Khandelwal†, Yogesh Chander†, Ram Kumar†, Himanshu Nagori†, Assim Verma†, Priyasi Mittal†, Riyesh T†, Sameer Kamboj‡, Sukhbir Singh Verma‡, Subhash Khatreja‡, Yash Pal†, Baldev R. Gulati†, Bhupendra N. Tripathi†, Sanjay Barua† and Naveen Kumar*†

1 Virology Laboratory, National Centre for Veterinary Type Cultures, ICAR-National Research Centre on Equines, Hisar, India, 2 Civil Hospital, Hisar, India

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved to generate several antigenic variants. These variants have raised concerns whether pre-existing immunity to vaccination or prior infection would be able to protect against the newly emerging SARS-CoV-2 variants or not. We isolated SARS-CoV-2 from the coronavirus disease 2019 (COVID-19)-confirmed patients in the beginning of the first (April/May 2020) and second (April/May 2021) waves of COVID-19 in India (Hisar, Haryana). Upon complete nucleotide sequencing, the viruses were found to be genetically related with wild-type (WT) and Delta variants of SARS-CoV-2, respectively. The Delta variant of SARS-CoV-2 produced a rapid cytopathic effect (24–36 h as compared to 48–72 h in WT) and had bigger plaque size but a shorter life cycle (~6 h as compared to the ~8 h in WT). Furthermore, the Delta variant achieved peak viral titers within 24 h as compared to the 48 h in WT. These evidence suggested that the Delta variant replicates significantly faster than the WT SARS-CoV-2. The virus neutralization experiments indicated that antibodies elicited by vaccination are more efficacious in neutralizing the WT virus but significantly less potent against the Delta variant. Our findings have implications in devising suitable vaccination, diagnostic and therapeutic strategies, besides providing insights into understanding virus replication and transmission.

Keywords: SARS-CoV-2, wild type, delta, antibody, cross-neutralization

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in 2019 in Wuhan, China, is responsible for the current pandemic of coronavirus disease 2019 (COVID-19) (Cao et al., 2020) and has resulted in more than 241.8 million infections and 4,919,755 deaths as of October 22, 2021 (WHO, 2021). Currently, there is no specific antiviral drug to treat COVID-19. However, vaccine is available, and currently, the world’s 7.9 billion population is being vaccinated to generate herd immunity. The original SARS-CoV-2, first detected in Wuhan, has undergone extensive mutations and has resulted in the generation of several antigenic variants. The major antigenic
variants include Alpha, Beta, Gamma, and Delta and are believed
to have originated in UK (December 2020), South Africa
(September 2020), Brazil (November 2020), and India (May
2021), respectively (Duong, 2021). Currently, SARS-CoV-2
Delta variant (B.1.617.2) is predominantly circulating in India
and several other parts of the world (Noh et al., 2021; Sanyaolu
et al., 2021; Winger and Caspari, 2021). It has been classified as
a variant of concern and is believed to be 60% more transmissible
than the Alpha variant (B.1.1.7) (Duong, 2021). New variants of
interest are Eta, Iota, Kappa, Lambda, and Mu, and many more
are likely to emerge (Areo et al., 2021; Janik et al., 2021; Parums,
2021). The emergence and widespread prevalence of new SARS-
CoV-2 variants can reduce the effectiveness of the current
crudes and pose a significant threat to combat the pandemic
(Becker et al., 2021; Duong, 2021; Ferraz et al., 2021; Sharun
et al., 2021). Besides vaccine efficacy, antigenic variations
may also affect the capability of the diagnostic tests, which are
based on WT SARS-CoV-2. Besides, there is a significant gap in
our understanding about the life cycle of the wild-type (WT) and
Delta strains of SARS-CoV-2. This study provides a comparative
insight on the growth characteristics and cross-neutralization of
WT and Delta strains of SARS-CoV-2.

MATERIALS AND METHODS

Cells
Vero cells were available at the National Centre for Veterinary
Type Cultures (NCVTC), Hisar, and grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
antibiotics and 10% fetal calf serum.

Nasopharyngeal Swabs and
Serum Samples
Nasopharyngeal swabs were received from the Civil Hospital
Hisar, Haryana (India). Serum samples from the vaccinated and/or
COVID-19-positive individuals were also received from the
Civil Hospital, Hisar. Depending on the exposure to SARS-CoV-
2, serum samples were categorized into the following types,
namely, infected during the first wave (W1), infected during the
second wave (W2), uninfected but vaccinated (V), infected
during the first wave and subsequently vaccinated (W1V), and
infected during the second wave and later vaccinated (W2V).
Paired samples were also collected from an individual who
succumbed to COVID-19 during both the first and second
waves (W1W2).

Ethics Statement
Samples were collected from patients by the authorized District
Medical Officer Hisar, India. A due consent was taken from the
patients before collection of the serum samples.

Virus Isolation
SARS-CoV-2 was propagated in Vero cells in the Biosafety Level
3 (BSL-3) laboratory of ICAR-National Research Centre on
Equines (ICAR-RCE), Hisar. The work was approved by the
Institute Biosafety Committee and Review Committee on
Genetic Manipulation (RCGM), Department of Biotechnology,
Government of India (No. BT/BS/17/436/2011-PID).

Virus isolation was attempted from the nasopharyngeal swabs
received for COVID-19 testing at our facility at ICAR-NRCE
Hisar. Nasopharyngeal swabs that were positive for SARS-CoV-2
genome with a cycle threshold (cT) value of <20.0 in quantitative
real-time PCR (qRT-PCR) were considered for virus isolation in
Vero cells. Samples that produced cytopathic effect (CPE) within
three successive blind passages in Vero cells were authenticated
and accessioned. Samples that did not produce CPE up to the
third blind passage were discontinued. The first attempt of virus
isolation was made in April 2020, which was the beginning of
COVID-19 pandemic in Haryana (India). Similarly, virus
isolation was also attempted from nasopharyngeal swabs (n =
11) that were collected following the onset of the second wave in
India (April/May 2021).

Identification
The viral RNA was extracted using QIAamp Viral RNA Mini Kit
(Qiagen, Hilden, Germany). This was followed by amplification
of SARS-CoV-2 RdRp and E gene using LabGun COVID-19
Assay (Labgenomics Co., Ltd., Suwon-si, Republic of Korea)
using CFX96 PCR Detection Systems (BioRad, USA).

Complete Genome Sequencing of
the Viral Isolates
Viral RNA was extracted by TRIzol Reagent (Invitrogen, CA,
USA). Complementary DNA (cDNA) was synthesized as per
the protocol described by the manufacturer (Fermentas, Hanover,
USA) and sent to Clevergene Biocorp Pvt Ltd. (Bengaluru, India)
for complete genome sequencing. Briefly, first-strand cDNA
reactions were converted to double-stranded DNA (dsDNA).
The double-stranded cDNA fragments obtained were cleaned up
by using 1.8× of AMPure XP beads (Catalog no. A63881,
Beckman Coulter). The purified cDNA was run on the tape to
check the fragment size of cDNA. The library concentration
was determined in a Qubit.3 Fluorometer (Catalog no. Q33216,
Life Technologies) using the Qubit dsDNA High Sensitivity Assay
Kit (Catalog no. Q3254, Thermo Fisher Scientific). The library
quality assessment was done using Agilent D5000 Screen Tape
System (Catalog no. 5067-5588, Agilent) in a 4150 Tape Station
System (Catalog no. G2992AA, Agilent).

The sequence data were generated using Illumina HiSeq. Data
quality was checked using FastQC (Ewels et al., 2016) software.
Raw sequence reads were processed to remove adapter sequences
and low-quality bases using fastp (Chen et al., 2018). To make
consensus sequences, quality trimmed were aligned to respective
genomes transcriptome using bwa-mem. The mean depth was
calculated using mosdepth (Pedersen and Quinlan, 2018) and
sambamba (Tarasov et al., 2015). From the aligned bam files,
variants were called with –ploidy 1 option, and consensus
sequence genomes were built using the reference genome using
bcftools from the samtools package (Li et al., 2009). SnpEff v 4.1
was used to annotate the variants (Cingolani et al., 2012) with
respect to their reference sequence.
The complete nucleotide sequences of WT and Delta strains reported in this study were compared with the original SARS-CoV-2, reported for the first time in late 2019 in Wuhan, China (GenBank Accession Number MN996528.1), and with a reference Delta strain (GenBank Accession Number OK091006.1), and the mutations were identified by using an online server (https://www.gisaid.org).

**Plaque Assay**
SARS-CoV-2 plaque assay was performed as described previously (Kumar et al., 2018; Kumar et al., 2019). Briefly, the confluent monolayers of Vero cells were infected with 10-fold serial dilutions of SARS-CoV-2 for 1 h at 37°C, after which the infecting medium was replaced with an agar overlay containing equal volume of 2× L-15 medium and 1% agar. Upon development of plaques, the agar overlay was removed, and the plaques were stained by 1% crystal violet.

**Virus Neutralization Assay**
The virus neutralization assay was carried out as per the previously described method with some modifications (Kumar et al., 2020; Kumar et al., 2021). Serum samples were initially heated at 56°C for 30 min to inactivate the complement. Vero cells were grown in 96-well tissue culture plates at ~90 confluency. Twofold serum dilutions (in 50 µl volume) were made in phosphate-buffered saline (PBS) and incubated with equal volume of SARS-CoV-2 for 1 h at 37°C, after which the infecting medium was replaced with an agar overlay containing equal volume of 2× L-15 medium and 1% agar. Upon comparison of the nucleotide/amino acid sequences, rather than any variants of concern (observed later during the pandemic), these viruses were found to be more closely related with the original SARS-CoV-2 reported during the early stage of pandemic in China. Hereinafter, we refer them as wild-type (WT) SARS-CoV-2 strain(s), although only one of them was used for the detailed investigation in this study. Six amino acid mutations (Table 1) were observed in the WT as compared to the Wuhan SARS-CoV-2.

Likewise, three virus isolates from the second wave (April/May 2021) were also subjected to complete genome sequencing (sequence will be provided on request). On BLAST search, these sequences were found to be closely related with the Delta variants of SARS-CoV-2 and possess all the Delta-specific signature mutations (Table 1). One of the Delta strains (employed for detailed investigations in this study) that was compared with the reference Delta strain showed six amino acid mutations (Table 1).

**Virus Isolation**
The first COVID-19-positive case in Haryana was reported from the Gurugram district on March 17, 2021. By April 2020, it had spread to almost the entire state. Our laboratory started testing for COVID-19 from April 12, 2020. Some of the samples that were received in April/May 2020 and had a CT value of <20 were subjected to virus isolation. In April/May 2020, out of the 11 nasopharyngeal swabs subjected to virus isolation, only 4 produced CPE up to the third blind passage, 3 of which were further authenticated and deposited with accession numbers of VTCCA294 (SARS-CoV-2/India/2020/tc/Hisar/4907), VTCCA295 (SARS-CoV-2/India/2020/tc/Hisar/2710), and VTCCA296 (SARS-CoV-2/India/2020/tc/Hisar/1469) at the National Repository of Animal Microbes (NCFITC, Hisar, Haryana; www.ncvitc.org.in). The virus with accession number VTCCA295 was used as a prototype of WT SARS-CoV-2 for various biological assays described in this study.

On the onset of the second wave of COVID-19 (April/May 2021) in India, we again attempted virus isolation from the samples received from the Hisar district of Haryana. Out of the 11 nasopharyngeal swabs, 1 swab sample produced CPE even on the first blind passage, whereas 2 produced CPE during the second blind passage. These three virus isolates were further authenticated and deposited at the repository described above with accession numbers, namely, VTCCA2318 (SARS-CoV-2/India/2021/tc/Hisar/177124), VTCCA2319 (SARS-CoV-2/India/2021/tc/Hisar/177405), and VTCCA2320 (SARS-CoV-2/India/2021/tc/Hisar/177961). The virus with accession number VTCCA2319 was later used as a prototype of Delta variant of SARS-CoV-2 for various biological assays described in this study.

At passage level 5 (Vero cells), whereas WT SARS-CoV-2 took 3–4 days in producing appreciable CPE in Vero cells, the Delta variant was able to produce significant cell death within 24–36 h, suggesting a higher replication rate of the Delta variant. Besides, the nature of the CPE was also strikingly different;
whereas infection of WT virus resulted in cell rounding, detachment, degeneration, and occasionally small syncytia (Figure 1A), the Delta variant produced elongated and extremely large syncytia, besides inducing degeneration and detachment of the cells (Figure 1A). Most importantly, plaques produced by the Delta variant were much larger in size as compared to the WT SARS-CoV-2 (Figure 1B).

### SARS-CoV-2 Life Cycle (One-Step Growth Curve)

In order to determine the length of the viral life cycle, Vero cells were infected with high MOI (MOI = 5), and the virus released in the infected cell culture supernatant at different times postinfection was quantified. There was no significant difference in the viral titers in the infected cell culture supernatant that were collected at 2 h postinfection (hpi) and 4 hpi in both WT (Figure 2A) and Delta (Figure 2B) strains. However, a sudden increase in viral titers was observed at 8 and 6 hpi, respectively in WT (Figure 2A) and Delta (Figure 2B) strains. This increase in viral titers was presumably due to the appearance of infectious progeny virus particles in the infected cell culture supernatant and hence indicated the completion of viral life cycle at these time points. The higher viral titers in Delta as compared to the WT SARS-CoV-2-infected cells at 6 hpi (Figure 2C) suggested that Delta variant has a significantly shorter life cycle than the WT SARS-CoV-2. Although the peak viral titers (~10^7 pfu/ml) were almost similar in the supernatant collected from both WT (Figure 2A) and Delta (Figure 2B) strains, this was achieved significantly faster in Delta (~ 24 hpi) as compared to the WT strain (48 hpi) of SARS-CoV-2 (Figure 2C).

We also examined the kinetics of the SARS-CoV-2 RNA synthesis in cultured cells wherein Vero cells were infected with high MOI (MOI = 5), followed by quantifying the levels of SARS-CoV-2 RNA in the cell pellet at different times postinfection. A peak level of viral RNA was observed at ~9 h and ~6 h (Figure 3), respectively, in WT and Delta variant of SARS-CoV-2, which again suggested the faster replication (fitness) rate of the Delta variant.

### Cross-Neutralization Between WT and Delta Variants of SARS-CoV-2

We performed a virus neutralization assay in order to determine whether the sera from the COVID-19 vaccine recipient...
(Covishield/Covaxin used in India) and those who recovered naturally from the disease are able to neutralize the variants of concerns. There was a poor cross-reactivity between the sera derived from V/W1/W1V individuals with Delta variants; the antibody titers were in the range of 16–256 and 0–16 when neutralized with WT and Delta variant, respectively (Table 2). Likewise, sera derived from W2 individuals more effectively neutralized the Delta (titers range from 32 to 128) as compared to the WT SARS-CoV-2 (titers range from 0 to 32) (Table 2). The W2V individuals had higher antibody levels against both Delta and WT virus as expected. Exceptionally, two of the V-type sera (Table 2; SR134 and SR139) from diabetic patients were equally neutralized by both WT and Delta variants. Interestingly, one of the individuals (SR116A and SR116B, Table 2) developed clinical disease and tested positive for COVID-19 during both the first and second waves. Initially, 29 days following primary infection, the antibody titers in this individual were 32 and <8, respectively, against WT and Delta SARS-CoV-2, whereas at 18 days following secondary infection, the titers were 64 and 128, respectively.

**DISCUSSION**

Vaccinating the world’s 7.9 billion population against COVID-19 is a huge challenge (Asawapithulsert et al., 2021; Eichhorst, 2021; Perkins, 2021). As on September 2, 2021, only 40.1% of the world population has received at least one dose of the vaccine, while 38.92 million are now vaccinated. Only 1.8% of people in low-income countries have received at least one dose (Organization, 2021). Most of the vaccines being used worldwide are based on the SARS-CoV-2 strain(s) isolated in patients in December 2019 or early 2020. Since the virus rapidly undergoes mutations, a lot of antigenic variants have been reported. Currently, the major variants of concerns are Alpha, Beta, Gamma, and Delta (Lessells, 2021; Noh et al., 2021; Sander et al., 2021). New variants of interest are Eta, Iota, Kappa, Lambda, and Mu (Areo et al., 2021; Janik et al., 2021; Parums, 2021). New variants are believed to have more transmissibility and produce more lethal disease (Gravagnuolo et al., 2021). Most of these variants harbor mutations in the spike protein, thereby raising concerns whether pre-existing antibodies due to vaccination or infection (recovered individuals) would be able to protect against the newly emerging variants or not (Sharun et al., 2021). Besides vaccine efficacy, genetic/antigenic variations may also affect the capability of the diagnostic tests and therapeutic agents, most of which are based on WT SARS-CoV-2. Likewise, SARS-CoV-2 literature, particularly on the *in vitro* experiments that is mostly based on WT SARS-CoV-2, may lead to misleading conclusions if being extrapolated to understand the Delta virus biology. Despite several studies on virus isolation (Keyaerts et al., 2005), the precise natures of the kinetics of viral life cycle and nature of CPE produced by WT and Delta variants of SARS-CoV-2 are not well studied. Therefore, we compared the growth characteristics in terms of the kinetics of RNA synthesis, virus production (viral life cycle), plaque formation, and nature of CPE between WT and Delta variants of SARS-CoV-2.
Mutations in envelope proteins of RNA viruses have been shown to be associated with altered viral fitness, eventually affecting the viral plaque morphology (Mandary et al., 2019). In our study, we observed that the Delta variant of SARS-CoV-2 produces a rapid CPE within 24–36 h as compared to 48–72 h by WT. Besides, the Delta variant had bigger plaque size and a shorter life cycle (~ 6 h as compared to the ~8 h in WT). In SARS-CoV-2, D614G or P681R mutations (Table 1) were shown to enhance the replication fitness of Delta strain, although no alteration in plaque morphology was observed (Liu Y. et al., 2021; Plante et al., 2021), suggesting that plaque morphology and replication fitness may be determined by independent residues (Liu J. et al., 2021). In addition, the Delta variant rapidly synthesized viral RNA and achieved peak viral titers within 24 h as compared to the 48 h in WT. These observations on faster replication rate of the Delta variant reported in this study support the clinical finding, namely, high transmissibility of Delta variant (Gan et al., 2021; Xu et al., 2021).

Summarily, our neutralization experiments indicated that antibodies elicited by vaccination or infection with WT virus can more effectively neutralize WT SARS-CoV-2 (potential source of the available vaccine) but are significantly less potent against the Delta variant (Table 2), the strain that is currently circulating in India. Likewise, W2 sera were more strongly neutralized by Delta as compared to WT SARS-CoV-2 (Table 2). These findings on poor cross-neutralization are somewhat in agreement with few other recent findings (Hammerschmidt et al., 2021; Planas et al., 2021).

Exceptionally, two of the sera from vaccinated individuals (Table 2; SR134 and SR139), which had no prior history of COVID-19 infection but were diabetic, equally neutralized (antibody titer 128 against each) by both WT and Delta
variants. One possibility is that these vaccinated individuals could have been exposed to the Delta virus but did not develop any clinical disease. Although we cannot make any firm conclusions based on mere two samples, immune response against SARS-CoV-2 in diabetic patients could certainly be a matter of further research (Heald et al., 2021a; Heald et al., 2021b; Zheng et al., 2021).

Interestingly, one of the individuals (Table 2, SR116A and SR116B) tested positive for COVID-19 during both the first and second waves (also developed clinical disease on each occasion). The antibody titers in this individual were 32 and <8, respectively, against WT and Delta SARS-CoV-2, following 1 month after primary infection, whereas after 18 days following secondary infection, the titers were 64 and 128, respectively. This single but rare sample has again raised concern about the protective efficacy of cross-neutralizing antibodies elicited by vaccination in providing protection against Delta or other newly emerging strains of SARS-CoV-2.

Potential limitations of our work include the low number of infected individuals analyzed and the lack of data on cellular immune responses. Future studies on large number of sera for longer time periods to characterize the role of humoral responses could elaborate on the efficacy of the existing vaccine (prepared from WT SARS-CoV-2) against the circulating variants.

In conclusion, our results demonstrate that Delta variant is poorly neutralized by antibodies elicited by previous infection with SARS-CoV-2 or by vaccination.

### DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/genbank/, MW555317.
ETHICS STATEMENT

Samples were collected from patients by the authorized District Medical Officer Hisar, India. A due consent was taken from the patients before collection of the serum samples.

AUTHOR CONTRIBUTIONS

Conceptualization: NKu and BT. Formal analysis: NKu and BT. Funding acquisition: NKu and BG. Methodology: NKu, NKh, RK, AV, HN, YC, PM, RT, SV, SKa, and SKh. Writing—first draft: NKu. Writing—review and editing: NKu, NKh, RK, AV, HN, YC, PM, RT, SV, SKa, BT, BG, and YP. All authors contributed to the article and approved the submitted version.

REFERENCES

Areso, O., Joshi, P. U., Obrenovich, M., Tayahi, M., and Heldt, C. L. (2021). Single-Particle Characterization of SARS-CoV-2 Isolate and Comparison to Variants of Interest. Microorganisms 9, 1–6. doi: 10.3390/microorganisms 9081606

Asawapaithulsert, P., Pisutsan, P., and Matsee, W. (2021). Coincidence of Fever Following COVID-19 Vaccine and Endemic Tropical Diseases: A Challenge to Clinicians During the Global Rollout of COVID-19 Vaccination. J. Travel Med. 28, 1–2. doi: 10.1097/htm.taah109

Becker, M., Dulovic, A., Junker, D., Ruetalo, N., Kaiser, P. D., Pinilla, Y. T., et al. (2021). Immune Response to SARS-CoV-2 Variants of Concern in Vaccinated Individuals. Nat. Commun. 12, 3109. doi: 10.1038/s41467-021-23473-6

Cao, Y., Cai, K., and Xiong, L. (2020). Coronavirus Disease 2019: A New Severe Acute Respiratory Syndrome From Wuhan in China. Acta Virol. 64, 245–250. doi: 10.4149/av_2020_201

Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018). fastp: An Ultra-Fast All-in-One FASTQ Preprocessor. Bioinformatics 34, 1884–1890. doi: 10.1093/bioinformatics/bty560

Cingolani, P., Platts, A., Wang Le, L., Coon, M., Nguyen, T., Wang, L., et al. (2012). A Program for Annotating and Predicting the Effects of Single Nucleotide Polymorphisms, SnpEff: SNPs in the Genome of Drosophila Melanogaster Strain W1118; Iso-2; Iso-3. Fly (Austin) 6, 80–92. doi: 10.4161/fly.19695

Duong, D. (2021). Alpha, Beta, Delta, Gamma: What’s Important to Know About SARS-CoV-2 Variants of Concern? CMAJ 193, E1059–E1060. doi: 10.15033/ cmaj.1095949

Eichhorst, B. (2021). Vaccination Against COVID-19: A Challenge in CLL. Blood 137, 3153–3154. doi: 10.1182/blood.2021011955

Ewels, P., Magnusson, M., Lundin, S., and Kaller, M. (2016). MultiQC: Summarize High-Throughput Diagnostics and Dynamic Risk Assessment of SARS-CoV-2 Variants of Concern Is Driven by Low Affinity to Neutralizing Antibodies. Chem. Commun. (Camb.) 57, 6094–6097. doi: 10.1039/D1CC01747K

Gan, H. H., Twaddle, A., Marchand, B., and Gunsalus, K. C. (2021). Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface Can Identify High-Affinity Variants Associated With Increased Transmissibility. J. Mol. Biol. 433, 167051. doi: 10.1016/j.jmb.2021.167051

Gravagnuolo, A. M., Faqih, L., Cronshaw, C., Wynn, J., Klapper, P., and Wigginsworth, M. (2021). High Throughput Diagnostics and Dynamic Risk Assessment of SARS-CoV-2 Variants of Concern. Einstein 70, 103540. doi: 10.1016/ebiomed.2021.103540

Hammerschmidt, S. I., Bosnjak, B., Bernhardt, G., Friedrichsen, M., Ravens, I., Dopper-Jablanka, A., et al. (2021). Neutralization of the SARS-CoV-2 Delta Variant After Heterologous and Homologous BNT162b2 or ChAdOx1 NcoV-19 Vaccination. Cell. Mol. Immunol. 18, 1–2. doi: 10.1038/s41423-021-00755-x

Heald, A. H., Rea, R., Horne, L., Metters, A., Steele, T., Leivesley, K., et al. (2021a). Analysis of Continuous Glucose Tracking Data in People With Type 1 Diabetes (T1DM) After Covid-19 Vaccination Reveals Unexpected Link Between Immune and Metabolic Response, Augmented by Adjunctive Oral Medication. Int. J. Clin. Pract. e14714. doi: 10.22541/au.162381528.88125059/v1

Heald, A. H., Stedman, M., Horne, L., Rea, R., Whyte, M., Gibson, J. M., et al. (2021b). Analysis of Continuous Blood Glucose Data in People With Type 1 Diabetes (T1DM). After COVID-19 Vaccination Indicates a Possible Link Between the Immune and the Metabolic Response. J. Diabetes Sci. Technol. 15, 1204–1205. doi: 10.1177/19322968211026291

Holmes, K., Williams, C. M., Chapman, E. A., and Cross, M. J. (2010). Detection of sRNA Induced mRNA Silencing by RT-qPCR: Considerations for Experimental Design. BMC Res. Notes 3, 53. doi: 10.1186/1756-0500-3-53

Janik, E., Niemczewicz, M., Podgrocki, M., Majsterek, I., and Bijak, M. (2021). The Emerging Concern and Interest SARS-CoV-2 Variants. Pathogens 10, 1–13. doi: 10.3390/pathogens10060633

Keyerta, E., Vijgen, L., Maes, P., Neyts, J., and Van Ranst, M. (2005). Growth Kinetics of SARS-Coronavirus in Vero E6 Cells. Biochem. Biophys. Res. Commun. 329, 1147–1151. doi: 10.1016/j.bbrc.2005.02.085

Khandelwal, N., Chander, Y., Kumar, R., Riyesh, T., Dedar, R. K., Kumar, M., et al. (2020). Antiviral Activity of Apigenin Against Buffaloopox: Novel Mechanistic Insights and Drug-Resistance Considerations. Antiviral Res. 181, 104870. doi: 10.1016/j.antiviral.2020.104870

Kumar, N., Chander, Y., Kumar, R., Khandelwal, N., Riyesh, T., Chaudhary, K., et al. (2021). Isolation and Characterization of Lumpy Skin Disease Virus From Cattle in India. PLoS One 16, e0241022. doi: 10.1371/journal.pone.0241022

Kumar, N., Chander, Y., Riyesh, T., Khandelwal, N., Kumar, R., et al. (2020). Isolation and Characterization of Bovine Herpes Virus 5 (BoHV5) From Cattle in India. PLoS One 15, e0232093. doi: 10.1371/journal.pone.0232093

Kumar, R., Khandelwal, N., Chander, Y., Riyesh, T., Tripathi, B. N., Kashyap, S. K., et al. (2018). MNK1 Inhibitor as an Antiviral Agent Suppresses Buffaloopox Virus Protein Synthesis. Antiviral Res. 160, 126–136. doi: 10.1016/j.antiviral.2018.10.022

Kumar, N., Khandelwal, N., Kumar, R., Chander, Y., Rawat, K. D., Chaubey, K. K., et al. (2019). Inhibitor of Sarco/Endolysosomal Reticulum Calcium-ATPase Impairs Multiple Steps of Paramyxovirus Replication. Front. Microbiol. 10, 209. doi: 10.3389/fmicb.2019.00209

Lessells, R. J. (2021). SARS-CoV-2 Variants of Concern: The Knowns and Unknowns. Anaesth. Crit. Care Pain Med. 100, 100680. doi: 10.1016/j.jaccpm.2021.100680

Li, H., Handsaker, B., Wysocker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The Sequence Alignment/Map Format and SAMtools. Bioinformatics 25, 2078–2079. doi: 10.1093/bioinformatics/btp352

Liu, Y., Liu, J., Johnson, B. A., Xia, H., Ku, Z., Schindewolf, C., et al. (2021). Delta Spike P681R Mutation Enhances SARS-CoV-2 Fitness Over Alpha Variant. bioRxiv. doi: 10.1101/2021.08.12.456173

FUNDING

This work was supported by Indian Council of Agricultural Research, New Delhi (grant number IXXI4586 to NKu and NASF/ABA-8027/2020-21 to NKu and BG) and Science and Engineering Research Board, Department of Science and Technology, Government of India (grant number CVD/2020/000103 to NKu). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

We appreciate the participation of patients and healthy volunteers that allowed the realization of this study.
Khandelwal et al. Cross-Neutralization Between SARS-CoV-2 Variants

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org November 2021 | Volume 11 | Article 771524